China-based TG ImmunoPharma Co., Ltd has announced receiving the go-ahead from the US FDA to carry out a Phase I clinical study for its TGI-2/NM1F, a novel anti-PVRIG therapeutic antibody, in patients with advanced solid tumors. Currently, no drugs targeting PVRIG have been approved globally.
TGI-2/NM1F: A Promising Anti-PVRIG Therapeutic Antibody
TGI-2/NM1F is a humanized IgG1 monoclonal antibody targeting PVRIG for the treatment of malignant cancers. The antibody binds to PVRIG with high affinity to block the PVRIG/PVRL2 interaction and restore the antitumor immune functions of both NK cells and T cells. Preclinical data suggest that TGI-2/NM1F has a long half-life and is well tolerated at very high doses in nonhuman primates. Treatment with TGI-2/NM1F as a monotherapy demonstrates significant inhibition of tumor growth in human tumor xenograft mouse models, while it further enhances the antitumor effect in combination with a PD-1 inhibitor.
TG ImmunoPharma: A Leader in Cancer Immunotherapy
TG ImmunoPharma is a biotech company founded by the R&D team led by Dr. Zhigang Tian, members of the Chinese Academy of Engineering and Academia Europaea, dedicated to the development of novel immunotherapeutic drugs. As one of the leaders in NK cell research globally and with the goal of strengthening the antitumor function of human NK cells and other lymphocytes, the team has focused on the discovery of novel targets for cancer immunotherapy for years. The company gained Pre-Series A financial backing in April 2022, having partnered up with Harbour BioMed (HKG: 2142) and GenScript Biotech Corporation (HKG: 1548) in 2021.-Fineline Info & Tech
